Clonal evolution in chronic lymphocytic leukemia detected by fluorescence in situ hybridization and conventional cytogenetics after stimulation with CpG oligonucleotides and interleukin-2: a prospective analysis
Language English Country England, Great Britain Media print-electronic
Document type Comparative Study, Evaluation Study, Journal Article, Research Support, Non-U.S. Gov't
PubMed
24246692
DOI
10.1016/j.leukres.2013.10.019
PII: S0145-2126(13)00374-3
Knihovny.cz E-resources
- Keywords
- Chronic lymphocytic leukemia, Clonal evolution, CpG oligonucleotides, Cytogenetics, Fluorescence in situ hybridization, Interleukin-2,
- MeSH
- Lymphocyte Activation drug effects MeSH
- Leukemia, Lymphocytic, Chronic, B-Cell genetics pathology MeSH
- Adult MeSH
- In Situ Hybridization, Fluorescence * MeSH
- Interleukin-2 pharmacology MeSH
- Clonal Evolution * MeSH
- Middle Aged MeSH
- Humans MeSH
- Oligodeoxyribonucleotides pharmacology MeSH
- Prospective Studies MeSH
- Chromosome Banding * MeSH
- Aged MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Evaluation Study MeSH
- Research Support, Non-U.S. Gov't MeSH
- Comparative Study MeSH
- Names of Substances
- CPG-oligonucleotide MeSH Browser
- Interleukin-2 MeSH
- Oligodeoxyribonucleotides MeSH
Chronic lymphocytic leukemia (CLL) patients may acquire new chromosome abnormalities during the course of their disease. Clonal evolution (CE) has been detected by conventional chromosome banding (CBA), several groups also confirmed CE with fluorescence in situ hybridization (FISH). At present, there are minimal prospective data on CE frequency determined using a combination of both methods. Therefore, the aim of our study was to prospectively assess CE frequency using a combination of FISH and CBA after stimulation with CpG oligonucleotides and interleukin-2. Between 2008 and 2012, we enrolled 140 patients with previously untreated CLL in a prospective trial evaluating CE using FISH and CBA after stimulation. Patients provided baseline and regular follow-up peripheral blood samples for testing. There was a median of 3 cytogenetic examinations (using both methods) per patient. CE was detected in 15.7% (22/140) of patients using FISH, in 28.6% (40/140) using CBA, and in 34.3% (48/140) of patients by combining both methods. Poor-prognosis CE (new deletion 17p, new deletion 11q or new complex karyotype) was detected in 15% (21/140) of patients and was significantly associated with previous CLL treatment (p=0.013). CBA provides more complex information about cytogenetic abnormalities in CLL patients than FISH and confirms that many patients can acquire new abnormalities during the course of their disease in a relatively short time period.
References provided by Crossref.org
